Engineered immune cells take on deadliest brain cancer

NCT ID NCT06482905

Recruiting now Disease control Sponsor: Tcelltech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called TX103 CAR-T cells for people with recurrent or progressive grade 4 glioma, a very aggressive brain cancer. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. The main goals are to check safety and find the best dose, with 52 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TX103 CAR-T cells (immune cells engineered to target B7-H3 on cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with recurrent grade 4 glioma, a very aggressive brain cancer.
What could go wrong: This is a very early (Phase 1) and small trial (52 people) focused on safety and dosing. CAR-T therapy can cause serious side effects like cytokine release syndrome, and it's unknown if it will shrink tumors or extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA WHO GRADE Ⅳ GLIOMA

Contacts and locations

Locations

Beijing Tiantan Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Mayo Clinic in Arizona
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.